Glioblastoma is a fatal brain tumor and the FDA has been advised that a new device to treat this condition has to be to be approved.
 
What advisory panel states is not what the FDA is suppose to follow but in normal course of action, the FDA does follow the recommendations.
 
A patient carries on his back a battery pack that is of six pounds, which generates an intermediate-frequency electrical field and this is what the NovoTTF-100A System or NovoTTF does for zapping tumors.
 
Experts state that people whose cancers have bounced back following regular kinds of treatments like chemotherapy, surgery and radiation will be the ones who will use this.
 
Three questions were formed on which a vote was suppose to be put by twelve voting members of the Neurological Devices Advisory Panel and these questions were about safety, effectiveness and if the risks were outweighed by benefits.
 
In people who were terminally ill, a 12-0 was voted by the advisory panel when it came to the safety of the device.
 
Effectiveness however formed a ground of the panel being completely divided making it being divided in half and half with six people stating no and six stating a yes.